alimentiv-and-satisfai-health-announce-commercial-availability-of-highly-innovative-ai-powered-scoring-tool-for-the-assessment-of-ulcerative-colitis-in-stage-i-through-iv-clinical-trials

Alimentiv and Satisfai Health Announce Commercial Availability of Highly Innovative AI-Powered Scoring Tool for the Assessment of Ulcerative Colitis in Stage I through IV Clinical Trials

 

Alimentiv, a global contract research organization (CRO) providing clinical trials, central image management, precision medicine, and real-world evidence services to the pharmaceutical and biotechnology industries, and Satisfai Health, a Vancouver-based software company focused on the application of artificial intelligence to gastrointestinal disease assessment, are announcing the commercial availability of Satisfai Health’s Certai product as an automated, AI-powered solution for the secondary analysis of endoscopic video in Phase I through IV IBD clinical trials. Certai will be exclusively available to Alimentiv’s sponsor clients and will provide advanced data insights alongside Alimentiv’s central reading services.

Certai was developed using a comprehensive global dataset of anonymized IBD colonoscopy videos, with data labeling and clinical oversight from the globally leading experts on the assessment and scoring of IBD within clinical trials. “Using Certai is like having the world’s leading IBD experts on your shoulder,” said Dr. Michael Byrne, CEO, Satisfai Health. Dr. Remo Pannacione, a leading global expert in the development of therapies for IBD, further commented that “the standardization of disease scoring by AI brings us an entirely new level of insight that can make a real difference to how we control and analyze data, ultimately powering better outcomes across the board.”

Certai will be made available in Alimentiv’s multi-modal imaging platform, Notō, offering a unique end-to-end solution supporting image review and centralized scoring. “The technical integration of Satisfai’s products into Alimentiv’s software provides a foundation for the future advanced capabilities in digital biomarker identification, precision medicine, and companion diagnostics. We are very excited to bring these advancements in digital analysis into our portfolio,” said Jeff Smith, CEO, Alimentiv.  In securing these exciting new technologies for sponsor client use, Alimentiv will continue to lead the industry with more detailed, accurate analysis, highly competitive trial costs, and faster timelines. Certai is not a medical device and is not used by healthcare professionals for clinical decision-making or for the provision of patient care.

Get involved!

Get Connected!
Connect with like-minded people, start groups, share files and documents, create group video meetings, attend conferences, and more.

Comments

No comments yet